Bioorganic and medicinal chemistry (2020)
Update date:2022-07-29
Topics:
Ambler, Catherine M.
Arnold, Eric
Banker, Mary Ellen
Clark, James D.
Dowty, Martin E.
Efremov, Ivan V.
Fensome, Andrew
Flick, Andrew
Gerstenberger, Brian S.
Gifford, Roger S.
Gopalsamy, Ariamala
Hegen, Martin
Jussif, Jason
Limburg, David C.
Lin, Tsung H.
Pierce, Betsy S.
Sharma, Raman
Trujillo, John I.
Vajdos, Felix F.
Vincent, Fabien
Wan, Zhao-Kui
Xing, Li
Yang, Xiaojing
Yang, Xin
Herein, we disclose a new series of TYK2/ JAK1 inhibitors based upon a 3.1.0 azabicyclic substituted pyrimidine scaffold. We illustrate the use of structure-based drug design for the initial design and subsequent optimization of this series of compounds. One advanced example 19 met program objectives for potency, selectivity and ADME, and demonstrated oral activity in the adjuvant-induced arthritis rat model.
View Morewebsite:http://www.synchemie.com/
Contact:+86-574-87642758
Address:Room 901, Yinyi Bund Building, 132 Renmin Road
Contact:+86-710-3516804
Address:Number 83,Panggong road,Xiangcheng District,Xiangyang ,Hubei
Hangzhou Ocean Chemical Co., Ltd.
website:http://www.hzoceanchem.com
Contact:+86-571-88025872, 28272092, 28272096
Address:Room 623 ,Building No 1 , COFCO Radius Commercial Center Xiwen Road, Xiacheng District, Hangzhou, Zhejiang Province, China
Shanghai Pengkai Chemical Co.,Ltd
Contact:+86-21-60526671
Address:No.4226 Duzhuang Rd Minhang District Shanghai China
Contact:86-21-34622192,13917187091,21-34622765
Address:No. 500 Caobao Road Shanghai P.R China
Doi:10.1016/S0040-4020(01)81726-9
(1988)Doi:10.1016/S0040-4039(00)96613-9
(1987)Doi:10.1016/j.bmcl.2013.09.041
(2013)Doi:10.1016/S0040-4039(00)96656-5
(1987)Doi:10.1021/bi100538b
(2010)Doi:10.1002/chem.201400315
(2014)